Study: Combo therapy cuts death risk from cryptococcal meningitis

04/4/2013 | HealthDay News

A treatment regimen that combines the antifungal drugs amphotericin B and flucytosine can lower cryptococcal meningitis patients' risk of death by 40% compared to amphotericin B alone, a study in the New England Journal of Medicine showed. Survivors also had lower odds of disability if they were treated with flucytosine, the researchers found.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC